Wall Street analysts expect that Teligent Inc (NASDAQ:TLGT) will post sales of $17.58 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Teligent’s earnings, with the highest sales estimate coming in at $17.60 million and the lowest estimate coming in at $17.55 million. Teligent posted sales of $16.75 million during the same quarter last year, which indicates a positive year over year growth rate of 5%. The firm is expected to issue its next earnings report on Wednesday, August 14th.
According to Zacks, analysts expect that Teligent will report full year sales of $73.69 million for the current year, with estimates ranging from $73.07 million to $74.30 million. For the next fiscal year, analysts anticipate that the company will post sales of $98.00 million, with estimates ranging from $95.00 million to $101.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Teligent.
Teligent (NASDAQ:TLGT) last issued its earnings results on Monday, March 18th. The company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.16). Teligent had a negative return on equity of 103.41% and a negative net margin of 73.56%. The business had revenue of $16.78 million during the quarter, compared to analysts’ expectations of $17.73 million.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in TLGT. BlackRock Inc. increased its position in shares of Teligent by 0.5% during the 3rd quarter. BlackRock Inc. now owns 3,463,605 shares of the company’s stock valued at $13,681,000 after purchasing an additional 16,198 shares during the last quarter. Vanguard Group Inc increased its position in shares of Teligent by 0.7% during the 3rd quarter. Vanguard Group Inc now owns 2,249,427 shares of the company’s stock valued at $8,885,000 after purchasing an additional 15,800 shares during the last quarter. NJ State Employees Deferred Compensation Plan increased its position in shares of Teligent by 15.8% during the 4th quarter. NJ State Employees Deferred Compensation Plan now owns 220,000 shares of the company’s stock valued at $301,000 after purchasing an additional 30,000 shares during the last quarter. New Jersey Better Educational Savings Trust increased its position in shares of Teligent by 11.1% during the 4th quarter. New Jersey Better Educational Savings Trust now owns 100,000 shares of the company’s stock valued at $137,000 after purchasing an additional 10,000 shares during the last quarter. Finally, AMI Asset Management Corp increased its position in shares of Teligent by 1.9% during the 4th quarter. AMI Asset Management Corp now owns 2,714,292 shares of the company’s stock valued at $3,719,000 after purchasing an additional 50,558 shares during the last quarter. 64.59% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:TLGT opened at $0.68 on Tuesday. Teligent has a fifty-two week low of $0.66 and a fifty-two week high of $4.52. The company has a quick ratio of 0.79, a current ratio of 1.46 and a debt-to-equity ratio of 14.43. The stock has a market capitalization of $46.73 million, a price-to-earnings ratio of -2.06 and a beta of 1.45.
Teligent Company Profile
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.